{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:01:19Z","timestamp":1790510479401,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007197","name":"United States Public Health Service","doi-asserted-by":"publisher","award":["GM62882"],"award-info":[{"award-number":["GM62882"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Core Grant","award":["P30 EY11373"],"award-info":[{"award-number":["P30 EY11373"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.06.026","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:31:09Z","timestamp":1498325469000},"page":"465-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Natalia","family":"Mast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha","family":"Saadane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Valencia-Olvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Constans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-9278","authenticated-orcid":false,"given":"Hiroyuki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Landreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Pikuleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.06.026_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/07853898909149188","article-title":"The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease","volume":"21","author":"Abraham","year":"1989","journal-title":"Ann. Med."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(88)90462-X","article-title":"Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease","volume":"52","author":"Abraham","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib4","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1074\/jbc.M116.723577","article-title":"Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity","volume":"291","author":"Anderson","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib5","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1523\/JNEUROSCI.1663-14.2014","article-title":"Thalamic NMDA receptor function is necessary for patterning of the thalamocortical somatosensory map and for sensorimotor behaviors","volume":"34","author":"Arakawa","year":"2014","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1219988","article-title":"The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol","volume":"336","author":"Barrett","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(01)02277-7","article-title":"On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells","volume":"314","author":"Bogdanovic","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awv384","article-title":"CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease","volume":"139","author":"Boussicault","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3940(00)01466-X","article-title":"Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases","volume":"293","author":"Bretillon","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib10","doi-asserted-by":"crossref","first-page":"34674","DOI":"10.1074\/jbc.M402324200","article-title":"Differential expression of cholesterol hydroxylases in Alzheimer's disease","volume":"279","author":"Brown","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1471-4159.2009.06502.x","article-title":"Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits","volume":"112","author":"Bryan","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib12","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1073\/pnas.0913828107","article-title":"ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD","volume":"107","author":"Bryleva","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib13","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1093\/hmg\/ddv268","article-title":"Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology","volume":"24","author":"Burlot","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2009.10.006","article-title":"Inflammation, microglia, and Alzheimer's disease","volume":"37","author":"Cameron","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib15","doi-asserted-by":"crossref","first-page":"e1787","DOI":"10.21769\/BioProtoc.1787","article-title":"A\u03b2 extraction from murine brain homogenates","volume":"6","author":"Casali","year":"2016","journal-title":"Bio protocol"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/ejn.12911","article-title":"Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus","volume":"41","author":"Chali","year":"2015","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib17","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","article-title":"Nuclear receptors and lipid physiology: opening the X-files","volume":"294","author":"Chawla","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cmet.2006.11.012","article-title":"Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice","volume":"5","author":"Chen","year":"2007","journal-title":"Cell. Metab."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib19","first-page":"721","article-title":"Intracellular trafficking of the beta-secretase and processing of amyloid precursor protein","volume":"63","author":"Chia","year":"2011","journal-title":"IUBMB Life"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11481-015-9627-8","article-title":"ABCA1 is necessary for bexarotene-mediated clearance of soluble amyloid beta from the Hippocampus of APP\/PS1 mice","volume":"11","author":"Corona","year":"2016","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib21","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gkl767","article-title":"qPrimerDepot: a primer database for quantitative real time PCR","volume":"35","author":"Cui","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0896-6273(95)90300-3","article-title":"Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1","volume":"14","author":"Das","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005072-199704000-00001","article-title":"The pathogenesis of senile plaques","volume":"56","author":"Dickson","year":"1997","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib25","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/brain\/awv166","article-title":"CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease","volume":"138","author":"Djelti","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib26","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1073\/pnas.92.6.2313","article-title":"Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation","volume":"92","author":"Eriksson","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib27","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1073\/pnas.081620098","article-title":"Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in\u00a0vitro and in\u00a0vivo","volume":"98","author":"Fassbender","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s11064-008-9623-y","article-title":"Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress","volume":"33","author":"Ferrera","year":"2008","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1474-9726.2011.00681.x","article-title":"Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-beta in amplifying neuronal damage in Alzheimer's disease: three partners in crime","volume":"10","author":"Gamba","year":"2011","journal-title":"Aging Cell."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2006.11.022","article-title":"Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma","volume":"25","author":"Ghisletti","year":"2007","journal-title":"Mol. Cell."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1749-6632.2000.tb05379.x","article-title":"Regulation of cytokine secretion and amyloid precursor protein processing by proinflammatory amyloid beta (A beta)","volume":"917","author":"Gitter","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ncb1313","article-title":"Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin","volume":"7","author":"Grimm","year":"2005","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bbalip.2010.05.002","article-title":"Role of amyloid beta in lipid homeostasis","volume":"1801","author":"Grosgen","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib34","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1007\/s11033-012-1472-8","article-title":"Association between alpha1-antichymotrypsin signal peptide -15A\/T polymorphism and the risk of Alzheimer's disease: a meta-analysis","volume":"39","author":"Guan","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-7364-7-22","article-title":"Update of the human and mouse SERPIN gene superfamily","volume":"7","author":"Heit","year":"2013","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/mt.2009.175","article-title":"Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease","volume":"18","author":"Hudry","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/383728a0","article-title":"An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha","volume":"383","author":"Janowski","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm820","article-title":"Reciprocal regulation of inflammation and lipid metabolism by liver X receptors","volume":"9","author":"Joseph","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2006.01.107","article-title":"Oxidized low density lipoprotein suppresses lipopolysaccharide-induced inflammatory responses in microglia: oxidative stress acts through control of inflammation","volume":"342","author":"Kim","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib41","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1073\/pnas.081612998","article-title":"Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10","volume":"98","author":"Kojro","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0006-8993(98)01274-8","article-title":"The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells","volume":"818","author":"Kolsch","year":"1999","journal-title":"Brain. Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib43","doi-asserted-by":"crossref","first-page":"11394","DOI":"10.1073\/pnas.0805556105","article-title":"Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation","volume":"105","author":"Kotti","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib44","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1073\/pnas.0600316103","article-title":"Brain cholesterol turnover required for geranylgeraniol production and learning in mice","volume":"103","author":"Kotti","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.molcel.2009.07.021","article-title":"Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes","volume":"35","author":"Lee","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-2-20","article-title":"Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment","volume":"2","author":"Lefterov","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib48","first-page":"735","article-title":"Melanocortins as innovative drugs for ischemic diseases and neurodegenerative disorders: established data and perspectives","volume":"20","author":"Leone","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib49","doi-asserted-by":"crossref","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","article-title":"Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease","volume":"285","author":"Lewis","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-5728(98)00096-4","article-title":"Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype","volume":"88","author":"Licastro","year":"1998","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib51","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.neurobiolaging.2013.04.008","article-title":"Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice","volume":"34","author":"Loffler","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib52","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","article-title":"cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain","volume":"96","author":"Lund","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib53","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1073\/pnas.93.18.9799","article-title":"Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation","volume":"93","author":"Lutjohann","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-2275(20)32052-6","article-title":"Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients","volume":"41","author":"Lutjohann","year":"2000","journal-title":"J.\u00a0Lipid Res."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2017.06.026_bib55","first-page":"S102","article-title":"24S-hydroxycholesterol: a marker of brain cholesterol metabolism","volume":"36","author":"Lutjohann","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0197-4580(96)00112-1","article-title":"Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides","volume":"17","author":"Ma","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/372092a0","article-title":"Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments","volume":"372","author":"Ma","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib58","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/00001756-199511270-00004","article-title":"IL-1 beta and TNF alpha, but not IL-6, induce alpha 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG","volume":"6","author":"Machein","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2006.06.009","article-title":"Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma","volume":"24","author":"Maes","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068534","article-title":"Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?","volume":"8","author":"Maioli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.abb.2004.05.012","article-title":"Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N- and C-terminal modifications","volume":"428","author":"Mast","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib62","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M110.143313","article-title":"Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain","volume":"285","author":"Mast","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib63","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","article-title":"Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice","volume":"289","author":"Mast","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.abb.2009.01.002","article-title":"Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase","volume":"483","author":"Mast","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib65","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/mol.112.080424","article-title":"In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine","volume":"82","author":"Mast","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib66","doi-asserted-by":"crossref","first-page":"14284","DOI":"10.1021\/bi035512f","article-title":"Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain","volume":"42","author":"Mast","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib67","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1167\/iovs.10-6021","article-title":"Cholestenoic acid is an important elimination product of cholesterol in the retina: comparison of retinal cholesterol metabolism with that in the brain","volume":"52","author":"Mast","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/mol.113.085902","article-title":"Antifungal azoles: structural insights into undesired tight binding to cholesterol-metabolizing CYP46A1","volume":"84","author":"Mast","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib69","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1074\/jbc.M112.438754","article-title":"Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response","volume":"288","author":"Mast","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib70","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1523\/JNEUROSCI.0630-12.2012","article-title":"beta-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage","volume":"32","author":"Mohamed","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib71","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/cdd.2012.161","article-title":"Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology","volume":"20","author":"Moon","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib72","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.npp.1300668","article-title":"Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models","volume":"30","author":"Morihara","year":"2005","journal-title":"Neuropsychopharm"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib73","first-page":"826","article-title":"Apolipoprotein B immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in senile dementia of Alzheimer type","volume":"31","author":"Namba","year":"1991","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib74","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1523\/JNEUROSCI.21-05-01444.2001","article-title":"Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease","volume":"21","author":"Nilsson","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib75","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib76","first-page":"251","article-title":"Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1","volume":"23","author":"Ohno","year":"2006","journal-title":"Neuropsychopharm"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib77","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.neubiorev.2011.12.014","article-title":"Neural and cellular mechanisms of fear and extinction memory formation","volume":"36","author":"Orsini","year":"2012","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib78","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.plipres.2011.06.002","article-title":"Cholesterol metabolism in neurons and astrocytes","volume":"50","author":"Pfrieger","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib80","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/emmm.201202215","article-title":"Amyloid precursor protein controls cholesterol turnover needed for neuronal activity","volume":"5","author":"Pierrot","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.devbrainres.2003.09.015","article-title":"Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse","volume":"146","author":"Quan","year":"2003","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib82","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/cne.21605","article-title":"Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain","volume":"507","author":"Ramirez","year":"2008","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib83","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00005072-198911000-00009","article-title":"A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition","volume":"48","author":"Rozemuller","year":"1989","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib84","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1146\/annurev.biochem.78.072407.103859","article-title":"Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain","volume":"78","author":"Russell","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/glia.22423","article-title":"Regulation of microglia activation and deactivation by nuclear receptors","volume":"61","author":"Saijo","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib86","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.3697","article-title":"Single App knock-in mouse models of Alzheimer's disease","volume":"17","author":"Saito","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.autrev.2011.09.005","article-title":"Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly","volume":"11","author":"Sardi","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib88","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.neuro.2012.03.001","article-title":"Fibromyalgia, mood disorders, and intense creative energy: a1AT polymorphisms are not always silent","volume":"33","author":"Schmechel","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib89","first-page":"267","article-title":"Tissue processing prior to protein analysis and amyloid-beta quantitation","volume":"299","author":"Schmidt","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.physbeh.2014.05.041","article-title":"Behavioral and EEG changes in male 5xFAD mice","volume":"135","author":"Schneider","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3233\/JAD-2008-13402","article-title":"Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders","volume":"13","author":"Schwab","year":"2008","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib92","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1194\/jlr.M900174-JLR200","article-title":"The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase (CYP46A1) in\u00a0vitro and in\u00a0vivo","volume":"51","author":"Shafaati","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib93","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2796.2011.02389.x","article-title":"Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in\u00a0vivo","volume":"270","author":"Shafaati","year":"2011","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib94","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.95.11.6460","article-title":"Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons","volume":"95","author":"Simons","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib95","doi-asserted-by":"crossref","first-page":"e34078","DOI":"10.1371\/journal.pone.0034078","article-title":"Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals","volume":"7","author":"Song","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib96","doi-asserted-by":"crossref","first-page":"28163","DOI":"10.1074\/jbc.C112.360800","article-title":"Human serum albumin can regulate amyloid-beta peptide fiber growth in the brain interstitium: implications for Alzheimer disease","volume":"287","author":"Stanyon","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1096-9861(19980713)396:4<511::AID-CNE7>3.0.CO;2-4","article-title":"Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease","volume":"396","author":"Styren","year":"1998","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib98","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1152\/jn.00890.2015","article-title":"Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices","volume":"115","author":"Sun","year":"2016","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib99","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1073858414568122","article-title":"24(S)-Hydroxycholesterol as a modulator of neuronal signaling and survival","volume":"22","author":"Sun","year":"2016","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib100","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","article-title":"TopHat: discovering splice junctions with RNA-Seq","volume":"25","author":"Trapnell","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib101","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","article-title":"Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation","volume":"28","author":"Trapnell","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib102","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuroscience.2013.12.001","article-title":"Vitamin E is essential for Purkinje neuron integrity","volume":"260","author":"Ulatowski","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.06.026_bib103","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1096\/fj.13-231456","article-title":"Suppression of amyloid-beta production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking","volume":"27","author":"Urano","year":"2013","journal-title":"Faseb J."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib104","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.0022-3042.2001.00724.x","article-title":"Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease","volume":"80","author":"Van Ess","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib105","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.010124","article-title":"Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases","volume":"5","author":"Vance","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/JAD-2010-1209","article-title":"Alterations in brain cholesterol metabolism in the APPSLxPS1mut mouse, a model for Alzheimer's disease","volume":"19","author":"Vanmierlo","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/nbdi.2001.0470","article-title":"Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains","volume":"9","author":"Wahrle","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1107\/S0907444908004046","article-title":"Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1","volume":"64","author":"White","year":"2008","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib109","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1074\/jbc.M114.559062","article-title":"Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) in the brain","volume":"289","author":"Yu","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib110","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","article-title":"Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors","volume":"104","author":"Zelcer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.06.026_bib111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2006.11.007","article-title":"Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes","volume":"183","author":"Zhang-Gandhi","year":"2007","journal-title":"J.\u00a0Neuroimmunol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T01:09:12Z","timestamp":1659143352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":111,"alternative-id":["S002839081730299X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.026","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}